ClinicalTrials.gg
CompletedNCT00775242Updated Aug 25, 2009

Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.

A Phase 2/3 interventional study of Estradiol and Progesterone and Estradiol and Progesterone in Menopause, sponsored by Centro A.F. de Estudios Tecnologicos, S.A.. Completed at 1 site in Mexico. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-08-25.

Sponsored by Centro A.F. de Estudios Tecnologicos, S.A. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.

Enrollment
12th of 13
103 · median 431
Started
2007
with 3 others
Phase 2/3
Only one
of the 13
Registered
11th of 13
by date
Lead sponsor
1 of 13
Centro A.F. de Estudios Tecnologicos, S.A.

Among the 13 studies testing estradiol in Hot Flashes, this one is the 12th largest by enrollment, is one of 4 that started in 2007, is the only one in phase 2/3, and was the 11th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing estradiol in Hot Flashes as a file.
02

Study summary

During menopause a woman's body slowly produces less of the hormones estrogen and progesterone. Lower hormone levels in menopause may lead to hot flashes, vaginal dryness and osteoporosis. To help with these problems, women are often given estrogen or estrogen with progestin. The purpose of this study is to assess and compare the efficacy and safety of three doses of estradiol and progesterone for the treatment of the climacteric symptoms

Read the detailed description

Different formulations of estrogens and progestins have been used for the treatment of climacteric symptoms, however up to this date no formulation is completely satisfactory. Our company has developed a new technology for the preparation of controlled release bioerodible non-polymeric microspheres, these microspheres are capable of delivering doses of estradiol (E) and progesterone (P) at levels appropriate for the Hormonal Replacement Therapy (HRT) in order to relieve the climacteric symptoms. Non clinical and clinical studies have been conducted aimed at assessing the pharmacokinetics of these microspheres, at several doses of progesterone and estradiol. Results show that sustained plasma profiles for both steroids within the therapeutic range for several days are attained. On this basis, a new efficacy and safety study is going to be conducted with the purpose of assessing and defining the most appropriate doses of estradiol and progesterone for the HRT of the climacteric symptoms.

Three different doses of progesterone and estradiol (0.5 mg of E + 15 mg of P vs 1 mg of E + 20 mg of P vs 1 mg of E + 30 mg of P) will be compared in terms of their efficacy and safety to treat the climacteric symptoms in healthy postmenopausal women.

03

Conditions studied

  • Menopause

Browse trials for

Keywords

  • Menopause
  • Hormone Replacement Therapy
  • Microspheres
  • Progesterone
  • Estradiol
  • Hot flashes
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 40 and 65 years.
  • Perimenopausal subjects: Women showing spontaneous amenorrhea during the last 11 months.
  • subjects: Women with not less than 12 consecutive months of amenorrhea and FSH > 40 mIU/mL
  • Subjects showing vasomotor symptoms, not less than 3 hot flashes in a day or not less than 21 hot flashes in a week
  • Healthy subjects determined on the basis of a satisfactory complete clinical history, clinical laboratory tests, cervical cytology, endometrium and vaginal pelvic ultrasonography.
  • Subjects not receiving any hormonal treatment.

Exclusion criteria

Exclusion Criteria:

  • Subjects with background of endometrial hyperplasia or endometrial cancer.
  • Subjects with endometrial hyperplasia or endometrial cancer assessed by endometrial .
  • Perimenopausal subjects with background of abnormal uterine bleeding unless the Principal Clinical Investigator considers that this abnormality is secondary to the menopausal condition.
  • Subjects with to any medicament.
  • Subjects with direct family background of breast cancer.
  • Subjects with background of cardiovascular disease, renal, hepatic, metabolic, gastrointestinal, neurologic, endocrine, gynecologic disease including dysfunctional uterine bleeding, cervico uterine dysplasia, cancer, anemia, emotional disorders, or any other chronic degenerative disorders which could affect her participation in the study.
  • Subjects who require any medicament in the course of the study unless the Principal Clinical Investigator considers that there is no pharmacological interaction.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Estradiol and progesterone injection

    Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P

    Drug: Estradiol and Progesterone

Interventions

  • DrugEstradiol and Progesterone

    Drug pages: Estradiol · Progesterone

    Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.

    Also known as: estrogens and progestines

  • DrugEstradiol and Progesterone

    Drug pages: Estradiol · Progesterone

    Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period

    Also known as: Estrogens, Progestins

06

What researchers measure

Primary outcomes

  1. Change of frequency and intensity of vasomotor symptoms

    Time frame: 0, 1, 2, 3, 4, 5, 6 and 7 months

Secondary outcomes

  1. Frequency and intensity of vulvar and vaginal atrophy symptoms Vaginal pH Index of vaginal maturation (surface, intermediate and parabasal cells) Karyopiknotic index Lipids profile Utian quality of life scale Green climacteric symptoms scale

    Time frame: 0, 1, 2, 3, 4, 5, 6 and 7 months

07

Study locations

1 site
  • Centro A.F. de Estudios Tecnologicos, S.A.
    Mexico, DF 03100, Mexico
08

References and documents

Publications

  • Cortes-Bonilla M, Alonso-Campero R, Bernardo-Escudero R, Francisco-Doce MT, Chavarin-Gonzalez J, Perez-Cuevas R, Chedraui P. Improvement of quality of life and menopausal symptoms in climacteric women treated with low-dose monthly parenteral formulations of non-polymeric microspheres of 17beta-estradiol/progesterone. Gynecol Endocrinol. 2016 Oct;32(10):831-834. doi: 10.1080/09513590.2016.1183628. Epub 2016 May 17. PubMed 27187320 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2008
First posted
Oct 20, 2008
Start
Apr 2007
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Last update
Aug 25, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00775242
Lead sponsor
Centro A.F. de Estudios Tecnologicos, S.A.
First posted
Oct 20, 2008
Start date
Apr 2007
Primary completion
Nov 2008
Completion
Nov 2008
Last update
Aug 25, 2009

Study contacts

Manuel Cortes Bonilla, Ob/Gyn
principal investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Progesterone

Start the discussion